DC pole | Wartość | Język |
dc.contributor.author | Pyteraf, Jolanta | - |
dc.contributor.author | Pacławski, Adam | - |
dc.contributor.author | Jamróz, Witold | - |
dc.contributor.author | Mendyk, Aleksander | - |
dc.contributor.author | Paluch, Marian | - |
dc.contributor.author | Jachowicz, Renata | - |
dc.date.accessioned | 2022-04-13T09:56:17Z | - |
dc.date.available | 2022-04-13T09:56:17Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | "Pharmaceutics" (2022), Vol. 14, art. nr 843 | pl_PL |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.12128/23186 | - |
dc.description.abstract | Additive technologies have undoubtedly become one of the most intensively developing
manufacturing methods in recent years. Among the numerous applications, the interest in 3D
printing also includes its application in pharmacy for production of small batches of personalized
drugs. For this reason, we conducted multi-stage pre-formulation studies to optimize the process of
manufacturing solid dosage forms by photopolymerization with visible light. Based on tests planned
and executed according to the design of the experiment (DoE), we selected the optimal quantitative
composition of photocurable resin made of PEG 400, PEGDA MW 575, water, and riboflavin, a
non-toxic photoinitiator. In subsequent stages, we adjusted the printer set-up and process parameters.
Moreover, we assessed the influence of the co-initiators ascorbic acid or triethanolamine on the
resin’s polymerization process. Next, based on an optimized formulation, we printed and analyzed
drug-loaded tablets containing mebeverine hydrochloride, characterized by a gradual release of
active pharmaceutical ingredient (API), reaching 80% after 6 h. We proved the possibility of reusing
the drug-loaded resin that was not hardened during printing and determined the linear correlation
between the volume of the designed tablets and the amount of API, confirming the possibility of
printing personalized modified-release tablets. | pl_PL |
dc.language.iso | en | pl_PL |
dc.rights | Uznanie autorstwa 3.0 Polska | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/pl/ | * |
dc.subject | additive manufacturing | pl_PL |
dc.subject | solid dosage forms | pl_PL |
dc.subject | mebeverine hydrochloride | pl_PL |
dc.subject | DoE | pl_PL |
dc.subject | photopolymerization | pl_PL |
dc.subject | personalized drugs | pl_PL |
dc.title | Application and Multi-Stage Optimization of Daylight Polymer 3D Printing of Personalized Medicine Products | pl_PL |
dc.type | info:eu-repo/semantics/article | pl_PL |
dc.identifier.doi | 10.3390/pharmaceutics14040843 | - |
Pojawia się w kolekcji: | Artykuły (WNŚiT)
|